Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin.

Literature DB >> 1719141

Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin.

Y Kuroda¹, H Takashima, A Ikeda, C Endo, R Neshige, R Kakigi, H Shibasaki.

Abstract

Fourteen patients with HTLV-1-associated myelopathy were treated with high-dose intravenous gammaglobulin (IVGG). Ten received 10 g/day of IVGG and 4 received 400 mg/kg of body-weight/day of IVGG for 5 consecutive days. Improvement of spastic paraparesis was observed in 10 within 7 days of the commencement of IVGG. The therapeutic effects were sustained for more than 3 weeks in some patients. There were no side effects. Analysis of factors of relevance to the clinical improvement with IVGG showed that the beneficial response was preferentially found in patients having a high CSF titre of anti-HTLV-I antibodies, a high CSF IgG level and a marked brain MRI abnormality.

Entities: Disease Species

Mesh：

Substances：

Year: 1991 PMID： 1719141 DOI： 10.1007/bf00315327

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

27 in total

1. Improvement of neurologic function in chronic inflammatory demyelinating polyradiculoneuropathy following intravenous gamma-globulin infusion.

Authors: M Albala; M E McNamara; M Sokol; E Wyshock
Journal: Arch Neurol Date: 1987-03

2. Prevalence of HTLV-I-associated myelopathy among HTLV-I carriers in Saga, Japan.

Authors: H Shibasaki; S Tokudome; Y Kuroda; T Yanagawa; M Yoshihara
Journal: Neuroepidemiology Date: 1989 Impact factor: 3.282

3. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors: Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal: Lancet Date: 1984-10-06 Impact factor: 79.321

4. Necropsy findings in HTLV-I associated myelopathy.

Authors: S Akizuki; O Nakazato; Y Higuchi; K Tanabe; M Setoguchi; S Yoshida; Y Miyazaki; S Yamamoto; S Sudou; K Sannomiya
Journal: Lancet Date: 1987-01-17 Impact factor: 79.321

5. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors: J Fehr; V Hofmann; U Kappeler
Journal: N Engl J Med Date: 1982-05-27 Impact factor: 91.245

6. Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP).

Authors: Y Iwasaki
Journal: J Neurol Sci Date: 1990-04 Impact factor: 3.181

7. Impairment of cell-mediated immune responses in HTLV-I-associated myelopathy.

Authors: Y Kuroda; H Takashima
Journal: J Neurol Sci Date: 1990-12 Impact factor: 3.181

8. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin.

Authors: R P Kleyweg; F G van der Meché; J Meulstee
Journal: Neurology Date: 1988-10 Impact factor: 9.910

9. Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose gamma-globulin intravenously.

Authors: B W Boom; A Brand; J N Bavinck; J G Eernisse; M R Daha; B J Vermeer
Journal: Arch Dermatol Date: 1988-10

6. Lower-extremity Dynamometry as a Novel Outcome Measure in a Double-blind, Placebo-controlled, Feasibility Trial of Intravenous Immunoglobulin (IVIG) for HIV-associated Myelopathy.

Authors: Jessica Robinson-Papp; Mary Catherine George; Alexandra Nmashie; Donald Weisz; David M Simpson
Journal: Innov Clin Neurosci Date: 2018-02-01

Review 7. Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.

Authors: Mineki Saito
Journal: J Neurovirol Date: 2013-08-14 Impact factor: 3.739

7 in total

Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin.

1. Improvement of neurologic function in chronic inflammatory demyelinating polyradiculoneuropathy following intravenous gamma-globulin infusion.

2. Prevalence of HTLV-I-associated myelopathy among HTLV-I carriers in Saga, Japan.

3. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

4. Necropsy findings in HTLV-I associated myelopathy.

5. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

6. Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP).

7. Impairment of cell-mediated immune responses in HTLV-I-associated myelopathy.

8. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin.

9. Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose gamma-globulin intravenously.

10. Increases in helper inducer T cells and activated T cells in HTLV-I-associated myelopathy.

1. Pilot study of intravenous immunoglobulin in HIV-associated myelopathy.

Review 2. Passage of intravenous immunoglobulin and interaction with the CNS.

Review 3. Pathogenesis and treatment of HTLV-I associated myelopathy.

4. Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Review 5. Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.

6. Lower-extremity Dynamometry as a Novel Outcome Measure in a Double-blind, Placebo-controlled, Feasibility Trial of Intravenous Immunoglobulin (IVIG) for HIV-associated Myelopathy.

Review 7. Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.